INTELLIGENT BIO SOLUTIONS INC.

Intelligent Bio Solutions Inc. filed Amendment No. 1 to its 10-K, primarily to revise disclosures related to executive compensation, related-party transactions, and exhibits. The amendment clarifies capital raising transactions involving significant shareholders and the approval process for related-party transactions. It also details executive compensation for fiscal years 2025 and 2026, including salary, stock awards, and bonuses for CEO Harry Simeonidis and CFO Spiro Sakiris. Employment agreements were amended to adjust non-compete terms and enhance severance benefits, with specific provisions for termination and change in control scenarios. Additionally, the filing outlines the granting of restricted stock awards under the 2019 Long Term Incentive Plan, including performance-vesting awards tied to clinical trial, regulatory submission, and commercial milestones.

Intelligent Bio Solutions Inc. announced the completion of its Usability Study for the Intelligent Fingerprinting Drug Screening System. This study is a crucial component of its FDA 510(k) submission program, seeking U.S. market clearance for the detection of codeine. The study, conducted with CenExel Clinical Research, evaluated the system's ease of use and operator training effectiveness, reinforcing its potential for broad adoption. The company is on track to submit its 510(k) package in H2 2026, targeting entry into the multi-billion-dollar U.S. drug screening market.

Intelligent Bio Solutions Inc. announced the completion of its Interference Study for the Intelligent Fingerprinting Drug Screening System. This study, conducted with CenExel Clinical Research, evaluated the system's accuracy and reliability when exposed to common external contaminants like hand creams, alcohol, and dirt, specifically assessing its ability to detect codeine. The successful completion of this study is a significant step towards the company's FDA 510(k) submission, which remains on track for the second half of 2026, aiming for entry into the U.S. drug screening market.

Intelligent Bio Solutions Inc. reported that its total number of outstanding common shares as of the close of business on July 31, 2026, is 3,018,188. This updated share count is a result of shares sold through an At The Market Offering, the exercise of outstanding warrants, and the issuance of restricted common stock under an advisory agreement.

Intelligent Bio Solutions Inc. announced the completion of its Interference Study for the Intelligent Fingerprinting Drug Screening System. This study, conducted with CenExel Clinical Research, Inc., evaluates the system's accuracy and reliability against common external contaminants and is a crucial step for the company's FDA 510(k) submission for U.S. market clearance for codeine detection. Data analysis is ongoing, and the company remains on track to submit its 510(k) package in H2 2026, targeting entry into the multi-billion-dollar U.S. drug screening market.

Intelligent Bio Solutions Inc. announced it has addressed all cybersecurity and software-related review items for its upcoming FDA 510(k) submission, following independent third-party penetration testing. This resolution of all vulnerabilities significantly de-risks the submission process. The company remains on track to submit its 510(k) notification in calendar H2 2026, advancing its planned entry into the U.S. drug screening market.

Intelligent Bio Solutions Inc. announced the completion of precision testing for its Intelligent Fingerprinting Drug Screening System, a crucial step for its FDA 510(k) submission for U.S. market clearance for codeine detection. The testing involved over 1,600 tests across multiple sites and production runs, confirming consistent and reliable results. This data will strengthen the FDA application, bringing the company closer to entering the multi-billion-dollar U.S. drug screening market with its non-invasive technology.

Intelligent Bio Solutions Inc. announced the initiation of an Interference Study to support its FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for codeine detection. The study, involving 75 healthy adults, aims to validate the system's specificity and reliability against potentially interfering substances. Expected to conclude by mid-July 2026, the results will be a crucial part of the comprehensive clinical package for FDA clearance.

Intelligent Bio Solutions Inc. announced the initiation of an Interference Study to support its FDA 510(k) submission for U.S. market clearance of its Intelligent Fingerprinting Drug Screening System for codeine detection. The study, conducted with CenExel Clinical Research, will assess the system's accuracy and reliability in the presence of potentially interfering substances, enrolling 75 healthy adult participants. This critical FDA-required study is expected to be completed by mid-July 2026, with results included in the FDA submission package alongside data from concurrent Method Comparison and prior Cut-off Studies.

Intelligent Bio Solutions Inc. announced that its management team will participate in the Planet MicroCap Conference from June 16-18, 2026, in Las Vegas, NV. The company's presentation is scheduled for June 17, 2026, at 8:00 – 8:30 AM PDT. Intelligent Bio Solutions will also be available for one-on-one investor meetings throughout the event at Booth 413.